View Item 

Show simple item record

Epidermal Growth Factor Receptor Expression and Mutational Analysis in Synovial Sarcomas and Malignant Peripheral Nerve Sheath Tumors

dc.contributor.authorTawbi, Hussein
dc.contributor.authorThomas, Dafydd
dc.contributor.authorLucas, David R.
dc.contributor.authorBiermann, J. Sybil
dc.contributor.authorSchuetze, Scott M.
dc.contributor.authorHart, Anita L.
dc.contributor.authorChugh, Rashmi
dc.contributor.authorBaker, Laurence H.
dc.date.accessioned2017-12-15T16:48:30Z
dc.date.available2017-12-15T16:48:30Z
dc.date.issued2008-04
dc.identifier.citationTawbi, Hussein; Thomas, Dafydd; Lucas, David R.; Biermann, J. Sybil; Schuetze, Scott M.; Hart, Anita L.; Chugh, Rashmi; Baker, Laurence H. (2008). "Epidermal Growth Factor Receptor Expression and Mutational Analysis in Synovial Sarcomas and Malignant Peripheral Nerve Sheath Tumors." The Oncologist 13(4): 459-466.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/140003
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherEGFR
dc.subject.otherImmunohistochemistry
dc.subject.otherMalignant peripheral nerve sheath tumor
dc.subject.otherMutation analysis
dc.subject.otherSynovial sarcoma
dc.titleEpidermal Growth Factor Receptor Expression and Mutational Analysis in Synovial Sarcomas and Malignant Peripheral Nerve Sheath Tumors
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USA
dc.contributor.affiliationotherDepartment of Internal Medicine, Division of General Medicine, and
dc.contributor.affiliationotherDepartment of Orthopedic Surgery,
dc.contributor.affiliationotherDepartment of Pathology,
dc.contributor.affiliationotherDepartment of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA;
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/140003/1/onco0459.pdf
dc.identifier.doi10.1634/theoncologist.2007-0166
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceTsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005; 353: 133 – 144
dc.identifier.citedreferenceWong WW, Hirose T, Scheithauer BW et al. Malignant peripheral nerve sheath tumor: Analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998; 42: 351 – 360
dc.identifier.citedreferenceHruban RH, Shiu MH, Senie RT et al. Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer. 1990; 66: 1253 – 1265
dc.identifier.citedreferenceKourea HP, Bilsky MH, Leung DH et al. Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: A clinicopathologic study of 25 patients and 26 tumors. Cancer. 1998; 82: 2191 – 2203
dc.identifier.citedreferenceCarli M, Ferrari A, Mattke A et al. Pediatric malignant peripheral nerve sheath tumor: The Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005; 23: 8422 – 8430
dc.identifier.citedreferenceGhosh BC, Ghosh L, Huvos AG et al. Malignant schwannoma. A clinicopathologic study. Cancer. 1973; 31: 184 – 190
dc.identifier.citedreferenceWanebo JE, Malik JM, VandenBerg SR et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer. 1993; 71: 1247 – 1253
dc.identifier.citedreferenceFerrari A, Bisogno G, Macaluso A et al. Soft‐tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer. 2007; 109: 1406 – 1412
dc.identifier.citedreferenceThomas DG, Giordano TJ, Sanders D et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER‐2/neu in synovial sarcoma. Cancer. 2005; 103: 830 – 838
dc.identifier.citedreferenceYarden Y, The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37 suppl 4: S3 – S8
dc.identifier.citedreferenceUllrich A, Schlessinger J, Signal transduction by receptors with tyrosine kinase activity. Cell. 1990; 61: 203 – 212
dc.identifier.citedreferenceRosell R, Taron M, Reguart N et al. Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res. 2006; 12: 7222 – 7231
dc.identifier.citedreferenceCDM Fletcher, KK Unni, F Mertens. Pathology and Genetics of Tumours of Soft Tissue and Bone, Lyon, France: IARC Press, 2002, 1 – 427.
dc.identifier.citedreferenceNocito A, Kononen J, Kallioniemi OP et al. Tissue microarrays (TMAs) for high‐throughput molecular pathology research. Int J Cancer. 2001; 94: 1 – 5
dc.identifier.citedreferenceOlsen SH, Thomas DG, Lucas DR, Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol. 2006; 19: 659 – 668
dc.identifier.citedreferenceWang S, Saboorian MH, Frenkel E et al. Laboratory assessment of the status of Her‐2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000; 53: 374 – 381
dc.identifier.citedreferenceYantiss RK, Rosenberg AE, Sarran L et al. Multiple gastrointestinal stromal tumors in type I neurofibromatosis: A pathologic and molecular study. Mod Pathol. 2005; 18: 475 – 484
dc.identifier.citedreferenceNicholas MK, Lukas RV, Jafri NF et al. Epidermal growth factor receptor‐mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006; 12: 7261 – 7270
dc.identifier.citedreferenceJi H, Zhao X, Yuza Y et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 2006; 103: 7817 – 7822
dc.identifier.citedreferenceBasu TN, Gutmann DH, Fletcher JA et al. Aberrant regulation of Ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992; 356: 713 – 715
dc.identifier.citedreferenceDeClue JE, Heffelfinger S, Benvenuto G et al. Epidermal growth factor receptor expression in neurofibromatosis type 1‐related tumors and NF1 animal models. J Clin Invest. 2000; 105: 1233 – 1241
dc.identifier.citedreferenceLi H, Velasco‐Miguel S, Vass WC et al. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 2002; 62: 4507 – 4513
dc.identifier.citedreferencePerry A, Kunz SN, Fuller CE et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol. 2002; 61: 702 – 709
dc.identifier.citedreferenceLing BC, Wu J, Miller SJ et al. Role for the epidermal growth factor receptor in neurofibromatosis‐related peripheral nerve tumorigenesis. Cancer Cell. 2005; 7: 65 – 75
dc.identifier.citedreferenceMahller YY, Vaikunth SS, Currier MA et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther. 2007; 15: 279 – 286
dc.identifier.citedreferenceAlbritton KH, Rankin C, Coffin CM et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol. 2006; 24 18 suppl: 524s
dc.identifier.citedreferenceGusterson B, Cowley G, McIlhinney J et al. Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer. 1985; 36: 689 – 693
dc.identifier.citedreferenceBarbashina V, Benevenia J, Aviv H et al. Oncoproteins and proliferation markers in synovial sarcomas: A clinicopathologic study of 19 cases. J Cancer Res Clin Oncol. 2002; 128: 610 – 616
dc.identifier.citedreferenceBode B, Frigerio S, Behnke S et al. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol. 2006; 19: 541 – 547
dc.identifier.citedreferenceTerry J, Lubieniecka JM, Kwan W et al. Hsp90 inhibitor 17‐allylamino‐17‐demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin Cancer Res. 2005; 11: 5631 – 5638
dc.identifier.citedreferenceBlay J, Le Cesne A, Whelan J et al. Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2006; 24 18 suppl: 524s
dc.identifier.citedreferenceSW Weiss, JR Goldblum. Enzinger and Weiss’s Soft Tissue Tumors,, Fourth Edition, St. Louis: Mosby, Inc. 2001, 1 – 1622.
dc.identifier.citedreferenceFrancis P, Namlos HM, Muller C et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: Hypoxia‐induced transcription profile signifies metastatic potential. BMC Genomics. 2007; 8: 73
dc.identifier.citedreferenceBaird K, Davis S, Antonescu CR et al. Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res. 2005; 65: 9226 – 9235
dc.identifier.citedreferenceMF Brennan, ES Casper, LB Harrison, VT DeVita Jr, S Hellman, SA Rosenberg, et al. Soft tissue sarcoma. In Cancer: Principles and Practice of Oncology, Fifth Edition, Philadelphia: Lippincott‐Raven, 1997, 1738 – 1852.
dc.identifier.citedreferenceKawai A, Woodruff J, Healey JH et al. SYT‐SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998; 338: 153 – 160
dc.identifier.citedreferenceInagaki H, Nagasaka T, Otsuka T et al. Association of SYT‐SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol. 2000; 13: 482 – 488
dc.identifier.citedreferenceDucatman BS, Scheithauer BW, Piepgras DG et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986; 57: 2006 – 2021
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0459.pdf
Size:
1.419MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.